Avitar Inc(AVTI)
USD --+0.00%
Reward30Low
Risk45Moderate
📊75%Data
Thin -99% profit margin · Revenue down 47% YoY
AVTI
+0.0 · +0.00%
USD · OTCCE
Avitar Inc | Healthcare
Earnings Deterioration
Market Cap:20558
ℹ️
Reward Rating
30
Low
Bottom 1% (model universe)
75% data coverage
ℹ️
Risk Rating
45
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on AVTI to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Avitar Inc?

, through its subsidiaries, designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States.

AVTI · Verdict

Limited reward · moderate risk

AVTI stands out on volatility and balance sheet, but watch the profitability signal.

Based on 88% data coverage

AVTI · Verdict

What’s working & what to watch

Strengths 3

  • Volatility75/100

    Above average

  • Balance sheet68/100

    Current ratio 0.14

  • Valuation67/100

    Above average

Watchouts 3

  • Profitability9/100

    -73% net margin · 0% ROE

  • Growth15/100

    Rev -8.5% CAGR · earnings -2.2%

  • Cash flow35/100

    -73% net margin

Model-based scoring. For information only — not financial advice.

What is Avitar Inc?

, through its subsidiaries, designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid-based onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine, such as crack; marijuana; and methamphetamines, including meth and ecstasy. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 20.56K.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (30)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap20.56K
P/E RatioN/A
Dividend YieldN/A
52 Week HighN/A
52 Week LowN/A
Last AnnualSeptember
IPO Date8/11/1992
IncorporatedUSA
Shares OutstandingN/A
No. of Employees36
IndustryMedical Devices
ExchangeOTCCE
Beta-69.072
CurrencyUSD
WebsiteN/A